This editorial addresses the importance of diabetic gastroparesis as a marker of poor glycemic control, other vascular complications, and suboptimal therapeutic outcomes. Highlighting the need to prevent and manage gastroparesis, it tries to understand why the condition has not received its due share of attention. Complexities in screening, diagnosis, and management all contribute to the lack of focus on this autonomic neuropathy. The editorial reinforces the need to enhance awareness about diabetic gastroparesis and utilize good clinical sense and rational prescription writing in order to limit the impact of this complication.
Keywords: Acarbose; Alpha-glucosidase inhibitors; Autonomic neuropathy; Diabetic diarrhea; GLP1RA; Gastro-glycemic cycle; Metformin; Orlistat; SGLT1; Type 1 diabetes; Type 2 diabetes.